Douglas S. Scherr, M.D.

Urology
Douglas Scherr

For more information, please visit:

www.robotic-prostatectomy.com

Education:

1989 B.A. Cornell University, Arts & Sciences             Ithaca, New York

1994 M.D. The George Washington University Medical School   

      Washington, D.C.

Professional Experience:

1994-5   Intern, General Surgery

The George Washington University Hospital

1995-6   Junior Assistant Resident, General Surgery

The George Washington University Hospital

1996-9Resident in Urology

The James Buchanan Brady

Department of Urology

The New York Hospital-Cornell Medical Center

         New York, N.Y.

1999-00 Chief Resident in Urology

The James Buchanan Brady

Department of Urology

The New York Hospital-Cornell Medical Center

         New York, N.Y.

2000-02 Fellow, Urologic Oncology

Department of Urology

Memorial Sloan Kettering Cancer Center

         New York, N.Y.

7/01-6/02 Instructor in Urology

Department of Urology

Weill Medical College of Cornell University

       New York, N.Y.

7/02-Present Assistant Professor of Urology

Clinical Director, Urologic Oncology

Department of Urology

Weill Medical College of Cornell University

         New York, N.Y.

1/03-present Visiting Associate Physician

Rockefeller University Hospital

Rockefeller University

         New York, N.Y.

   

Professional Organizations:

   Diplomate, American Board of Urology

   Member, Society of Urologic Oncology   

      [Founding Member, Executive Committee, Young Urologic Oncology Society]

   Member, Society for Basic Urological Research

   Member, American Urological Association

   Member, New York Section of AUA, Co-Chair of Valentine Essay Meeting

   Member, Society of University Urologists

   Member, American Medical Association

   Lecturer, American Austrian Foundation

   Member, Cancer and Leukemia Group B (CALGB), GU Core

Board Certification:

   American Board of Urology (February, 2003)

Insurances

Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please feel free to contact this physician or this physician's practice as they may have individual contracts not included on this site.

  • AETNA [HMO]
  • AETNA [PPO]
  • AETNA [Medicare]
  • Aetna - Weill Cornell [POS]
  • CIGNA
  • Empire Blue Cross/Blue Shield [PPO]
  • Empire Blue Cross/Blue Shield [Mediblue (Senior)]
  • Empire Blue Cross/Blue Shield [EPO]
  • Empire Blue Cross/Blue Shield [HMO]
  • GHI [CBP]
  • Health Insurance Plan of NY (HIP)
  • Health Insurance Plan of NY (HIP) [Medicare]
  • Health Plus - Amerigroup
  • Medicare [Medicare]
  • Rockefeller University - CoreSource
  • United Empire
  • United Health Care

Publications

1.   Schultz PK, Herr HW, Zhang ZF, Bajorin DF, Seidman A, Sarkis A, Fair WR, Scherr DS, Bosl GJ, Scher HI. Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with five year follow-up. J Clin Oncol 12:1394-1401, 1994

2.   Scherr DS, Poppas DP. Laser tissue welding. In, Technologic Advances in Urology: Implications for the Twenty-first Century. Urol Clin N Amer 25: 123-35, 1998.

3.   Poppas DP, Scherr, DS. Laser tissue welding: a urological surgeon’s perspective. Haemophilia 4:456-462, 1998.

4.   Scherr, DS, Poppas DP. Laser welding in urology. AUA Update Series XVII: pp1-6, 1998.

5.   Scherr, DS, Chen A. Eid JF. A case report: In vivo excision of an angiomyolipoma from a living related renal transplant. J Urol, 163: 1859, 2000.

6.   Scherr, DS, Vaughan ED Jr, Wei JT, Chung M, Felson D. Allbright R, Knudsen BS: Bc1-2 and P53 Expression in clinically localized prostate cancer predicts the response of patients to external beam radiotherapy. J Urol 162: 12-16, 1999.

7.   Scherr, DS, Goldstein M. Comparison of bilateral versus unilateral varicocelectomy in men with palpable bilateral varicoceles. J Urol 162: 85-88, 1999.

8.   Scherr, DS, Eastham, J. Ohori M. Scardino PT. Prostate biopsy techniques and indications: when, where and how? Semin Urol Oncol 20(1):18-31, 2002.

9.   Scherr, DS, Pitts WR, Vaughan ED. DES Revisited: Anti-androgen therapy, osteoporosis and prostate cancer. J Urol, 167: 535-538, 2002.

10.   Scherr DS, Swindle and Scardino, PT. NCCN Guidelines for the Management of Prostate Cancer. Urology 61 (Suppl 2A): 14-24, 2003.

11.   Scherr, DS and Pitts, WR. Androgen Deprivation Therapy Without Estrogen Deprivation: The Non-Steroidal Effects of Estrogens in the Treatment of Prostate Cancer. J Urol 170(5): 1703-08, 2003

12.   Knudsen, BS, Gmyrek, GA, Inra, J, Scherr, DS, Vaughan, ED, Nanus, DM, Kattan, MW, Gerald, WL and Vande Woude, G. High Expression of the Met receptor in prostate cancer metastasis to bone. Urology, 60(60): 1113-1117, 2002.

13.   Scherr, DS, NG C, Munver, R, Sosa, RE, Vaughan, ED, et al. Practice Patterns Among Urologic Surgeons Treating Localized Renal Cell Carcinoma in the Laparoscopic Age: Technology vs. Oncology. Urology, 62(6): 1007-12, 2003.

14.   Richstone L, Scherr, DS, Reuter, VE, Snyder ME, Rabbani F, Kattan M and Russo P. Multifocal renal cortical tumors: frequency, associated clinicopathological features and impact on survival. J Urol, 171(2 pt 1): 615-20, 2004

15.   Chen, DY, Sosa, RE and Scherr, DS. Treatment of Adrenocortical Carcionoma: Contemporary Outcomes. Current Urology Reports, 5(1): 65-72, 2004

16.   Boorjian S, Tickoo S, Mongan N, Nanus D, Yu H, Bok D, Rando R, Scherr DS, and Gudas L. Loss of Lecithin:Retinol Acyltransferase (LRAT) Expression Correlates with Increased Pathologic Tumor Stage in Bladder Cancer. Cancer Res, 10: 3429-3437, May 15, 2004.

17.   Boorjian S, Ugras S, Mongan N, Gudas L, Tickoo S and Scherr DS. Androgen Receptor Expression is Inversely Correlated with Pathologic Tumor Stage in Transitional Cell Carcinoma of the Bladder. Accepted for Publication, Urology 64(2): 383-88, 2004.

18.   Boorjian S, Ng C, Sosa RE, Munver R, Delpizzo J, Vaughan ED and Scherr DS. Laser Ablation of Upper Tract Transitional Cell Carcinoma with the Intent on Kidney Preservation: Delay in time to Nephroureterectomy is Not Predictive of Poor Outcome. Accepted for Publication, Journal of Endourology, 2004.

19.    Boorjian, S., Scherr, D.S., Mongan, N.P., Zhuang, Y., Nanus, D.M., and

Gudas, L.J. Retinoid Receptor mRNA Expression Profiles in Human Bladder

Cancer Specimens. International Journal of Oncology, in press.

Book Chapters:

1.   Scherr, DS, Manyak MJ. BladderTumors and Calculi. In Sosa RE, Albala DM, Jenkins AD, Perlmutter, AP, eds. Textbook of Endourology. Philadelphia: WB Saunders and Co; 1997

2.   Scherr, DS, Bosworth J. Steckel J. Complications of brachytherapy in the treatment of localized prostate cancer. In: Smith, Teneja, et al, eds. Complications of Urologic Surgery. 3rd ed.2000.

Abstracts:   

      

1.   Scherr, DS, Simmons R. Russo P. Multifocal renal cell carcinoma: a descriptive analysis [Abstract]. Presented at American Urological Association, Anaheim, CA 2001.

2.   Scherr, DS, Pavlovich CP, Pitts, WR, Vaughan, ED. Collagen type I Crosslinked N-telopeptide as a urinary marker for osteoporosis in prostate cancer [Abstract]. Presented at American Urological Association, Atlanta, GA. 2000.

3.   Scherr, DS, Vaughan ED, Wei JT, Chung M, Felsen D, Albright R, Knudsen B. Bcl-2 and P53 expression in clinically localized prostate cancer can predict the response to external beam radiotherapy. [Abstract] Presented at American Urological Association, Dallas, TX. 1999.

4.   Scherr, DS, Choi B, Su LM, Moomjy M, Schlegel PN, Goldstein M. Pregnancy after testicular sperm extraction at the time of radical orchiectomy for cancer in a solitary testis. [Abstract] Presented at American Urological Association, San Diegeo, CA, 1998.

5.   Scherr, DS, Goldstein M: Comparison of bilateral vs unilateral varicocelectomy in men with palpable bilateral varicoceles [Abstract]. Presented at American Urological Association, San Diego, CA. 1998.

6.   Boorjian S, Ng C, Palese M, Sosa RE, Delpizzo J, Vaughan ED and Scherr DS. Delay in time to nephroureterectomy for patients undergoing ureteroscopic biopsy and laser tumor ablation of upper tract transitional cell carcinoma does not impact postoperative disease status. Presented at 2004 AUA, San Francisco, CA.

7.   Boorjian S, Ng C, Munver R, Sosa RE, Vaughan ED and Scherr DS. Abnormal urinary cytology predicts increased tumor recurrence in upper tract transitional cell carcinoma treated with endoscopic laser ablation. Presented at 2004 AUA, San Francisco, CA.

8.   Smith E, Albert M, Albert P, You X, Masse D and Scherr DS. Antigen cross presentation and cross priming in the treatment of superficial bladder cancer: The role of BCG-invoked specific CD8 T lymphocyte response against bladder tumor antigen. Presented at 2004 AUA, San Francisco, CA.

9.   Richstone L, Shah H, Chen H, Kattan M, Schlegel PN, Vaughan ED, Eastham J, Scardino PT and Scherr DS. Radical prostatectomy (RRP) in men>70 years old: Effect of age on upgrading, upstaging and accuracy of preoperative nomograms. Presented at 2004 AUA, San Francisco, CA.

10.   Boorjian S, Ng C, Munver R, Sosa RE, Vaughan ED and Scherr DS. Stage migration of upper tract transitional cell carcinoma: An argument for the continued role of endourologic diagnosis and treatment. Presented at 2004 AUA, San Francisco, CA.

Visiting Fellow/Professorships:

2/98   Visiting fellowship, Februrary, 1998; Salzburg General Hospital, Salzburg, Austria

12/02   Visiting Professorship, December 6-13, 2002, Salzburg Seminar, Salzburg, Austria

Invited Lectures:

10/02   The Changing Face of Hormonal Therapy in the Treatment of Prostate Cancer, Urology Grand Rounds, Brookdale Hospital, New York

9/03   A Modern Approach in the Treatment of Testicular Germ Cell Tumors. General Surgery Grand Rounds, Weill Medical College of Cornell University. Septmeber, 2003

Broadcast Interviews:

9/03   WNBC-TV New York: “Treatment Options for Prostate Cancer”

9/03   NY-1-TV New York: “Radiation and Surgical Treatments of Prostate Cancer”

2/04   WNBC-TV New York, “Screening for prostate cancer in African American Men”

Honors and Awards

Professional Honors/Awards:

William Beaumont Medical Research Honor Society

   

First Prize for Best Original Medical Essay, The William Shafirt Award, The George Washington University School of Medicine. “A crisis of unknown proportion: An empirical analysis of the American medical malpractice system.” 1994

   

First Prize for Clinical Investigation, Ferdinand C. Valentine Urology Residents Essay Meeting, “BCL-2 and P53 expression in clinically localized prostate cancer as predictive markers for the response to external beam radiotherapy.” 1998    

      

First Prize for Clinical Investigation, Society of University Urology Residents, Annual Chief Resident Meeting, Marietta, Georgia. “Anti-androgen therapy for prostate cancer and the prevention of osteoporosis: The role of DES.” 2000

      

Second Prize for Clinical Investigation, Ferdinand C. Valentine Urology Residents Essay Meeting, “Collagen Type I Crosslinked N-Telopeptide as a urinary marker for osteoporosis in prostate cancer: The role of Diethylstilbesterol (DES).” 2000   

      

Pfizer, Scholars in Urology Award, Awarded for advancing the scientific and clinical field of urology. 2000

   

Ferdinand C. Valentine Fellowship for Research in Urology. The New York Academy of Medicine. 2001-2002. Syndecan-1 expression in prostate cancer and the role of p27 in primary prostate epithelial cell transformation.

   

T32 Research Training Grant. Memorial Sloan Kettering Cancer Center. 2000-2002.

   

Edwin Beer Research Award. NY Academy of Medicine. Effective Tumor Immunotherapy in Transitional Cell Carcinoma of the Bladder. 2004-2006

   

Career Development Award. Kidney Urology Foundation of America. The role of the Pim-1 Oncoprotein in Prostate Carcinogenesis. 2004-2005